<b>Introduction:</b>S100 calcium-binding protein B
(S100B) is a biochemical marker of astroglial
damage.
<br/><b>Purpose:</b> To assess the pathophysiological
implications of S100B concentrations in blood
plasma and cerebrospinal fluid of patients with
neurodegenerative central nervous system disorders.
<br/><b>Materials and Methods:</b> In this study, we
determined and compare S100B concentrations in
blood plasma and cerebrospinal fluid obtained from
subjects diagnosed with Alzheimer's disease (n=20),
amyotrophic lateral sclerosis (n=12), multiple
sclerosis (n=40) and the reference group (n=20),
using enzyme-linked immunosorbent assay.
<br/><b>Results:</b> Concentrations of S100B in plasma
collected from patients diagnosed with Alzheimer's
disease (252,38±183,50 pg/mL) and multiple
sclerosis (164,92±250,14 pg/mL) were above
laboratory standards, but in patients with
amyotrophic lateral sclerosis (53,96±56,92 pg/mL)
and the reference group (2,12 pg/mL) were below
laboratory norms (N>75 pg/mL). Concentrations of
S100B in plasma collected from patients with
Alzheimer's disease (252,38±183,50 pg/mL) were
significantly higher than in patients with
amyotrophic lateral sclerosis (53,96±56,92 pg/mL)
(p<0,029). Concentrations of S100B in CSF
collected from the reference group (546,96±236,62
pg/mL) and from patients with Alzheimer's disease
(587,53±189,57 pg/mL), amyotrophic lateral
sclerosis (404,41±179,56 pg/mL), multiple sclerosis
(462,03±146,01 pg/mL) were very similar, and none
of pairwise comparisons reached statistical
significance.
<br/><b>Conclusions:</b> Results of our studies indicate the
importance of S100B protein concentration
assessment in blood in central nervous system
disorders differential diagnostics.